Acute Myeloid Leukemia (AML)NCT04813263
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
An observational study of Acute Myeloid Leukemia (AML), run by AbbVie at 281 sites in Japan.
Trial summary
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults. This study will assess how safe and effective oral venetoclax is in participants with AML. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Myeloid Leukemia (AML)
- How many people
- 424 participants
- Where
- 281 sitesJapan
- Study dates
- 28 May 2021to 30 Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Participants who are prescribed venetoclax for the treatment of Acute Myeloid Leukemia (AML) in routine clinical practice across Japan.
Who may be able to join
- All participants who are administered venetoclax for treatment of AML.
Who cannot join
- None
Trial locations and contacts
281 sites in 1 country.
281 sites in 1 country
Japan281 sites
Ageo Central General Hospital /ID# 254515
Ageo-shi, Saitama, 362-8588
Akita city Hospital /ID# 240008
Akita, Akita, 010-0933
Ako Central Hospital /ID# 239721
Ako-shi, Hyōgo, 678-0241
Hyogo Prefectural Amagasaki General Medical Center /ID# 239355
Amagasaki-shi, Hyōgo, 660-8550
Anan Medical Center /ID# 243781
Anan-shi, Tokushima, 774-0045
Anjou Kousei Hospital /ID# 244213
Anjo-shi, Aichi-ken, 446-8602
Aomori Prefectural Central Hospital /ID# 249442
Aomori, Aomori, 030-8553
Asahi General Hospital /ID# 233889
Asahi-shi, Chiba, 289-2511
TMG Asaka Medical Center /ID# 238761
Asaka-shi, Saitama, 351-0023
National Hospital Organization Beppu Medical Center /ID# 247894
Beppu-shi, Oita Prefecture, 874-0011
Kyushu University Beppu Hospital /ID# 249444
Beppu-shi, Oita Prefecture, 874-0838
Juntendo University Hospital /ID# 239096
Bunkyo-ku, Tokyo, 113-8431
Tokyo Medical And Dental University Hospital /ID# 242178
Bunkyo-ku, Tokyo, 113-8519
Chiba Aoba Municipal Hospital /ID# 240565
Chiba, Chiba, 260-0852
Chiba University Hospital /ID# 246011
Chiba, Chiba, 260-8677
Duplicate_Chiba Cancer Center /ID# 248122
Chiba, Chiba, 260-8717
Inoue Memorial Hospital /ID# 239351
Chiba, 260-0027
National Hospital Organization Chiba Medical Center /ID# 266755
Chiba, 260-0042
Shonan Tobu Sogo Hospital /ID# 241913
CHIGASAKI-shi, Kanagawa, 253-0083
St.Luke's International Hospital /ID# 248787
Chuo-ku, Tokyo, 104-8560
University of Yamanashi Hospital /ID# 246006
Chuo-shi, Yamanashi, 409-3821
Kita Fukushima Medical Center /ID# 250296
Date-shi, Fukushima, 960-0502
Medical Plaza Edogawa /ID# 244220
Edogawa Ward, Tokyo, 133-0052
Edogawa Hospital /ID# 239352
Edogawa-ku, Tokyo, 133-0052
Tama Medical Center /ID# 247954
Fuchū, Tokyo, 183-8524
Tokyo Metropolitan Children's Medical Center /ID# 252189
Fuchū, Tokyo, 183-8524
Kamifukuoka General Hospital /ID# 247890
Fujimino, Saitama, 356-0011
Fujioka General Hospital /ID# 255196
Fujioka-shi, Gunma, 375-0015
Fujisawa City Hospital /ID# 239375
Fujisawa-shi, 251-8550
Fukuiken Saiseikai Hospital /ID# 245062
Fukui-shi, Fukui, 918-8503
Fukuiken Saiseikai Hospital /ID# 246005
Fukui-shi, Fukui, 918-8503
Saiseikai Fukuoka Genaral Hospital /ID# 255193
Fukuoka, Fukuoka, 810-0001
National Hospital Organization Kyushu Medical Center /ID# 242026
Fukuoka, Fukuoka, 810-8563
Fukuoka Wajiro Hospital /ID# 238755
Fukuoka, Fukuoka, 811-0213
National Hospital Organization Kyushu Cancer Center /ID# 244217
Fukuoka, Fukuoka, 811-1395
Kyushu University Hospital /ID# 248781
Fukuoka, Fukuoka, 812-8582
Fukuoka University Hospital /ID# 244214
Fukuoka, Fukuoka, 814-0180
Japanese Red Cross Fukuoka Hospital /ID# 241181
Fukuoka, Fukuoka, 815-8555
Murakami Karindoh Hospital /ID# 256179
Fukuoka, Fukuoka, 819-0032
Harasanshin Hospital /ID# 240881
Fukuoka, 812-0033
Fukushima Minami Cardiovascular Hospital /ID# 252216
Fukushima, Fukushima, 960-8163
Fussa Hospital /ID# 240570
Fussa, Tokyo, 1970012
Gifu Municipal Hospital /ID# 241156
Gifu, Gifu, 500-8513
Gifu University Hospital /ID# 241183
Gifu, Gifu, 501-1194
Gifu Red Cross Hospital /ID# 240562
Gifu, Gifu, 502-8511
Nagasaki Goto Chuoh Hospital /ID# 239723
Goto-shi, Nagasaki, 853-0031
Shiroyama Hospital /ID# 246762
Habikino-shi, Osaka, 583-0872
Hachinohe Red Cross Hospital /ID# 250850
Hachinohe-shi, 039-1104
Tokai University Hachioji Hospital /ID# 266804
Hachiōji, 192-0032
National Hospital Organization Hamada Medical Center /ID# 250858
Hamada, Shimane, 697-0022
National Hospital Organization Mito Medical Center /ID# 239719
Higashi Ibaraki-gun, Ibaraki, 311-3193
Higashihiroshima Medical Center /ID# 250849
Higashihiroshima-shi, 739-0041
Tama-Hokubu Medical Center /ID# 245879
Higashimurayama-shi, Tokyo, 189-8511
Okitama Public General Hospital /ID# 242710
Higashiokitama-gun, Yamagata, 992-0601
Ishikiriseiki Hospital /ID# 246077
Higashiosaka, Osaka, 579-8026
Kansai Medical University Hospital /ID# 246820
Hirakata-shi, Osaka, 573-1191
National Hospital Organization Hirosaki General Medical Center /ID# 246008
Hirosaki-shi, Aomori, 036-8545
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 240880
Hiroshima, Hiroshima, 730-8619
Hiroshima Prefecture Hospital /ID# 252215
Hiroshima, 734-8530
Hitachi General Hospital /ID# 239376
Hitachi-shi, Ibaraki, 317-0077
KK Clinic Ichihara /ID# 250859
Ichihara, Chiba, 290-0035
Chiba Rosai Hospital /ID# 238767
Ichihara-shi, Chiba, 290-0003
Tokyo Dental College Ichikawa General Hospital /ID# 262626
Ichikawa-shi, Chiba, 272-0824
Aso Iizuka Hospital /ID# 266806
Iizuka, Fukuoka, 820-8505
Ikeda City Hospital /ID# 266802
Ikeda, 563-0025
Nara Hospital Kinki University Faculty of Medicine, /ID# 250295
Ikoma-shi, Nara, 630-0227
Nippon Medical Chiba Hokusoh Hospital /ID# 250297
Inzai-shi, Chiba, 270-1613
Itami City Hospital /ID# 233888
Itami-shi, Hyōgo, 6640006
Tokiwakai Jyoban Hospital /ID# 257007
Iwaki, Fukushima, 972-8322
Iwaki Kyoritsu General Hospital /ID# 260209
Iwaki, Fukushima, 973-8555
NHO Iwakuni Clinical Center /ID# 242170
Iwakuni-shi, Yamaguchi, 740-8510
Izumi City General Hospital /ID# 253204
Izumi-shi, Osaka, 594-0073
Osaka Women's and Children's Hospital /ID# 266805
Izumi-Shi, Osaka, 594-1101
Shimane University Hospital /ID# 255194
Izumo-shi, Shimane, 693-8501
Shimane Prefectural Central Ho /ID# 247895
Izumo-shi, Shimane, 693-8555
Imakiire General Hospital /ID# 258237
Kagoshima, Kagoshima-ken, 890-0051
Imamura General Hospital /ID# 234006
Kagoshima, Kagoshima-ken, 890-0064
Kainan Medical Center /ID# 240825
Kainan, Wakayama, 642-0002
Shonan Kamakura General Hospital /ID# 243053
Kamakura-shi, Kanagawa, 247-8533
Kameda General Hospital /ID# 241877
Kamogawa-shi, Chiba, 296-8602
JCHO Kanazawa Hospital /ID# 239379
Kanazawa, Ishikawa-ken, 920-0013
Medical Corporation Seijinkai Ikeda Hospital /ID# 242174
Kanoya-shi, Kagoshima-ken, 893-0024
Nara Medical University Hospital /ID# 251726
Kashihara-shi, Nara, 634-8522
The Jikei University Kashiwa Hospital /ID# 259510
Kashiwa-shi, Chiba, 277-8567
National Cancer Center Hospital East /ID# 241917
Kashiwa-shi, Chiba, 277-8577
Kawaguchi Municipal Medical Center /ID# 246080
Kawaguchi-shi, 333-0833
Teikyo University Mizonokuchi Hospital /ID# 244842
Kawasaki, Kanagawa, 213-8507
Kawasaki Municipal Hospital /ID# 241162
Kawasaki-shi, Kanagawa, 2100013
Japan Organization of Occupational Health and Society Kanto Rosai Hospital /ID# 255195
Kawasaki-shi, Kanagawa, 211-8510
Toranomon Hospital Kajigaya /ID# 256186
Kawasaki-shi, Kanagawa, 213-8587
Naga municipal Hospital /ID# 250259
Kinokawa, Wakayama, 649-6414
Kimitsu Chuo Hospital /ID# 248776
Kisarazu-shi, Chiba, 292-8535
Kishiwada City Hospital /ID# 234002
Kishiwada-shi, Osaka, 596-8501
Sumitomo Hospital /ID# 243774
Kita-ku, Osaka, 530-0005
Meirikai Chuo General Hospital /ID# 238751
Kita-ku, Tokyo, 114-0001
Kitakyusyu General Hospital /ID# 244212
Kitakyushu-shi, 800-0257
NHO Kokura Medical Center /ID# 257008
Kitakyusyu-shi, Fukuoka, 802-8533
Wakamatsu Hospital /ID# 251728
Kitakyusyu-shi, Fukuoka, 808-0024
Kitami Red Cross Hospital /ID# 251065
Kitami-shi, Hokkaido, 090-0026
Hyogo Prefectural Kobe Children's Hospital /ID# 245817
Kobe, Hyōgo, 650-0047
Kobe City Medical Center General Hospital /ID# 246010
Kobe, Hyōgo, 650-0047
Shinko Hospital /ID# 233782
Kobe, Hyōgo, 651-0072
Konan Medical Center /ID# 246079
Kobe, Hyōgo, 658-0064
Kochi Health Sciences Center /ID# 241182
Kochi, Kochi, 781-0111
Showa General Hospital /ID# 258235
Kodaira, Tokyo, 187-8510
Ohta Nishinouchi Hospital /ID# 243052
Koriyama-shi, Fukushima, 963-8558
Duplicate_The Cancer Institute Hospital Of JFCR /ID# 244216
Koto-ku, Tokyo, 135-8550
Shinkuki General Hospital /ID# 254516
Kuki-shi, Saitama, 346-0021
National Hospital Organization Kumamoto Medical Center /ID# 240886
Kumamoto, Kumamoto, 860-0008
Kumamoto University Hospital /ID# 239720
Kumamoto, Kumamoto, 8608556
Kumamoto Shinto General Hospital /ID# 242176
Kumamoto, Kumamoto, 862-8655
Kumamoto City Hospital /ID# 254494
Kumamoto-shi,Kumamoto, Kumamoto, 862-8505
Kawasaki Medical School Hospital /ID# 242709
Kurashiki-shi, Okayama-ken, 701-0192
Kurashiki Central Hospital /ID# 244205
Kurashiki-shi, Okayama-ken, 710-8602
Kurobe City Hospital /ID# 254493
Kurobe-shi, Toyama, 938-8502
Shinkoga Hospital /ID# 248786
Kurume, Fukuoka, 830-0033
Kurume University Hospital /ID# 240885
Kurume-shi, Fukuoka, 830-0011
St. Mary's Hospital /ID# 242332
Kurume-shi, Fukuoka, 830-8543
Omi Medical Center /ID# 258233
Kusatsu-shi, Shiga, 525-0066
University Hospital Kyoto Prefectural University of Medicine /ID# 244843
Kyoto, Kyoto, 602-8566
JCHO Kyoto Kuramaguchi Medical /ID# 248775
Kyoto, Kyoto, 603-8151
Japanese Red Cross Kyoto Daiichi Hosital /ID# 248124
Kyoto, Kyoto, 605-0981
Kyoto University Hospital /ID# 244844
Kyoto, Kyoto, 606-8507
National Hospital Organization Kyoto Medical Center /ID# 239092
Kyoto, Kyoto, 612-8555
Gunmaken Saiseikai Maebashi Hospital /ID# 239383
Maebashi, Gunma, 371-0821
Kaneda Hospital /ID# 238757
Maniwa, Okayama-ken, 719-3105
Masuda Red Cross Hospital /ID# 248780
Masuda-shi, Shimane, 698-0003
Chiba West General Hospital /ID# 262918
Matsudo-shi, Chiba, 270-2251
Watanabe Hospital /ID# 254476
Matsuyama, Ehime, 108-0073
Ehime Prefectural Central Hospital /ID# 261348
Matsuyama, Ehime, 790-0024
Matsuyama Shimin Hospital /ID# 243050
Matsuyama, Ehime, 790-0067
National Hospital Organization Shikoku Cancer Center /ID# 242171
Matsuyama, Ehime, 791-0280
Mishuku Hospital /ID# 239378
Meguro-ku, Tokyo, 153-0051
Kosei Chuo General Hospital /ID# 251011
Meguro-ku, Tokyo, 1538581
Mihara Shiromachi Hospital /ID# 246754
Mihara, Hiroshima, 723-0014
Toranomon Hospital /ID# 251010
Minato-ku, Tokyo, 105-8470
Kyorin University - Mitaka Campus /ID# 243777
Mitaka, 181-8611
Miyazaki Prefectural Miyazaki Hospital /ID# 251730
Miyazaki, Miyazaki, 880-8510
Koga General Hospital /ID# 248120
Miyazaki, Miyazaki, 8800041
University of Miyazaki Hospital /ID# 248805
Miyazaki, Miyazaki, 889-1692
Steel Memorial Muroran Hospita /ID# 231383
Muroran-shi, Hokkaido, 050-0076
Japanese Red Cross Musashino Hospital /ID# 246765
Musashino-shi, Tokyo, 180-8610
Miyazaki Prefectural Nobeoka Hospital /ID# 248715
Nabeoka-shi, Miyazaki, 882-0835
Jap Red Cross Nagasaki Genbaku /ID# 245029
Nagasaki, Nagasaki, 852-8104
Nagasaki University Hospital /ID# 245028
Nagasaki, Nagasaki, 852-8501
Nagoya City West Medical Center /ID# 250844
Nagoya, Aichi-ken, 462-8508
Aichi Cancer Center Hospital /ID# 243785
Nagoya, Aichi-ken, 464-8681
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 242173
Nagoya, Aichi-ken, 466-8650
Nagoya University Hospital /ID# 246009
Nagoya, Aichi-ken, 4668560
Nagoya City University Hospital /ID# 256177
Nagoya, Aichi-ken, 467-8602
Naha City Hospital /ID# 242027
Naha, Okinawa, 902-0061
University of the Ryukyus Hospital /ID# 246821
Nakagami-gun, Okinawa, 903-0215
Nara Prefecture General Medical Center /ID# 254492
Nara, Nara, 630-8054
Tsudanuma Central General Hospital /ID# 245890
Narashino-shi, Chiba, 275-0026
Japanese Red Cross Narita Hospital /ID# 243775
Narita-shi, Chiba, 286-8523
IUHW Narita Hospital /ID# 240574
Narita-shi, Chiba, 2868520
Chibaken Saiseikai Narashino Hospital /ID# 254491
Narshino-shi, Chiba, 275-8580
Tokushima Prefecture Naruto Hospital /ID# 239095
Naruto-shi, Tokushima, 772-0001
Miyagi Cancer Center /ID# 241879
Natori-shi, Miyagi, 981-1293
Juntendo Univ Nerima Hospital /ID# 250292
Nerima-ku, Tokyo, 177-0033
Seijukai Hospital /ID# 248788
Neyagawa, Osaka, 572-0022
Niigata University Medical & Dental Hospital /ID# 245027
Niigata, Niigata, 951-8520
Hyogo?Prefectural?Nishinomiya Hospital /ID# 239354
Nishinomiya-shi, Hyōgo, 662-0918
Hyogo Medical University Hospital /ID# 240569
Nishinomiya-shi, Hyōgo, 663-8501
Obihiro kosei Hospital /ID# 252218
Obihiro-shi, Hokkaido, 080-0024
National Center for Geriatrics and Gerontology /ID# 251683
Obu-shi, Aichi-ken, 474-8511
Odate Municipal General Hospital /ID# 258238
Odate-shi, Akita, 017-0885
Ogaki Municipal Hospital /ID# 239353
Ogaki-shi, Gifu, 503-8502
Oita Memorial Hospital /ID# 246818
Ōita, Oita Prefecture, 870-0854
Oita Prefectural Hospital /ID# 243786
Ōita, Oita Prefecture, 870-0855
Almeida Memorial Hospital /ID# 241916
Ōita, Oita Prefecture, 870-1133
Duplicate_Okayama University Hospital /ID# 240887
Okayama, Okayama-ken, 700-8558
Duplicate_Okayama University Hospital /ID# 243755
Okayama, Okayama-ken, 700-8558
Japanese Red Cross Okayama Hospital /ID# 240879
Okayama, Okayama-ken, 700-8607
Okayama Medical Center /ID# 243759
Okayama, Okayama-ken, 701-1192
Nakagami Hospital /ID# 243787
Okinawa-shi, Okinawa, 904-2195
P_Ome Municipal General Hospital /ID# 248778
Ōme, Tokyo, 198-0042
NHO Nagasaki Medical Center /ID# 240571
Omura-shi, Nagasaki, 856-8562
Omuta City Hospital /ID# 246823
Omuta-shi, Fukuoka, 836-0861
Kita-harima Medical Center /ID# 254490
Ono-shi, Hyōgo, 675-1327
Osaka Saiseikai Nakatsu Hospital /ID# 244209
Osaka, Osaka, 530-0012
Kitano Hospital /ID# 248785
Osaka, Osaka, 530-8480
Osaka City General Hospital /ID# 244210
Osaka, Osaka, 534-0021
National Hospital Organization Osaka National Hospital /ID# 238764
Osaka, Osaka, 540-0006
Otemae Hospital /ID# 250857
Osaka, Osaka, 540-0008
Osaka International Cancer Institute /ID# 248783
Osaka, Osaka, 541-8567
Japanese Red Cross Osaka Hospi /ID# 248784
Osaka, Osaka, 543-8555
Daini Osaka Police Hospital /ID# 240560
Osaka, Osaka, 543-8922
Osaka Metropolitan University Hospital /ID# 253203
Osaka, Osaka, 545-8586
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 243783
Osaka, Osaka, 550-0006
Kindai University Hospital /ID# 250851
Osakasayama-shi, Osaka, 589-8511
Osaki Citizen Hospital /ID# 249447
Osaki-shi, Miyagi, 989-6183
Iwate Prefectural Isawa Hospital /ID# 246819
Oshu-shi, Iwate, 0230864
Gunma Prefectural Cancer Center /ID# 242177
Ota-shi, Gunma, 373-8550
NHO Hiroshima-Nishi Medical center /ID# 238766
Otake-shi, Hiroshima, 739-0696
Saiseikai Shiga Hospital /ID# 239381
Rittō, Shiga, 520-3046
Saga Medical Center Koseikan /ID# 245816
Saga, Saga-ken, 840-8571
Nankai Medical Center /ID# 241914
Saiki-shi, 876-0857
Saitama City Hospital /ID# 240567
Saitama, 336-8522
Saitama Citizens Medical Center /ID# 252573
Saitama-shi, Saitama, 331-0054
Sakaide City Hospital /ID# 240563
Sakaidechō, Kagawa-ken, 7620043
Nihonkai General Hospital /ID# 242024
Sakata-shi, 998-0828
Toho University Sakura Medical Center /ID# 252187
Sakura-shi, Chiba, 285-8741
Sapporo Hokuyu Hospital /ID# 250856
Sapporo, Hokkaido, 003-0006
Homecareclinicn-Consept /Id# 239377
Sapporo, Hokkaido, 003-0803
Hokkaido Cancer Center /ID# 249441
Sapporo, Hokkaido, 003-0804
Sapporo Hokushin Hospital /ID# 241878
Sapporo, Hokkaido, 004-0052
Sapporo Kiyota Hospital /ID# 231385
Sapporo, Hokkaido, 004-0831
Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 249446
Sapporo, Hokkaido, 060-0033
Sapporo Medical University Hospital /ID# 252217
Sapporo, Hokkaido, 060-8543
Hokkaido University Hospital /ID# 244223
Sapporo, Hokkaido, 060-8648
Aiiku Hospital /ID# 239047
Sapporo, Hokkaido, 064-0804
Tenshi Hospital /ID# 243051
Sapporo, Hokkaido, 065-0012
Sasebo City General Hospital /ID# 238759
Sasebo-shi, Nagasaki, 857-0056
Miyagi Chuo Hospital /ID# 259511
Sendai, Miyagi, 980-0011
Tohoku University Hospital /ID# 243757
Sendai, Miyagi, 9808574
National Hospital Organization Sendai Medical Center /ID# 239384
Sendai, Miyagi, 983-8520
Metropolitan Research and Treatment Center for Blood Disorders /ID# 231384
Setagaya Ward, Tokyo, 156-0052
National Center for Child Health and Development /ID# 243778
Setagaya-ku, Tokyo, 157-8535
National Hospital Organization Shibukawa Medical Center /ID# 245026
Shibukawa-shi, Gunma, 377-0280
Japanese Red Cross Medical Center /ID# 239385
Shibuya-ku, Tokyo, 150-8935
Duplicate_Dokkyo Medical University Hospital /ID# 246764
Shimotsuga-gun, Tochigi, 321-0293
Ishibashi General Hospital /ID# 243762
Shimotsuke, Tochigi, 329-0502
NTT Medical Center Tokyo /ID# 240566
Shinagawa-ku, Tokyo, 141-8625
Tokyo Medical University Hospital /ID# 252571
Shinjuku-ku, Tokyo, 160-0023
Center hospital of the National Center for Global Health and Medicine /ID# 256189
Shinjuku-ku, Tokyo, 162-8655
Shirakawa Kosei General Hosp. /ID# 245815
Shirakawa-shi, Fukushima, 961-0005
Iwate Medical University Hospital /ID# 251009
Shiwa-gun, Iwate, 028-3695
Shizuoka Saiseikai Genaral Hospital /ID# 239722
Shizuoka, Shizuoka, 422-8527
Tokuyama Central Hospital /ID# 242380
Shunan-shi, Yamaguchi, 745-8522
Kawakita General Hospital /ID# 257009
Suginami-ku, Tokyo, 166-8588
Tokyo Metropolitan Bokutoh Hospital /ID# 241912
Sumida-ku, Tokyo, 130-8575
The Fraternity Memorial Hospital /ID# 251685
Sumida-ku, Tokyo, 1308587
Sunagawa City Medical Center /ID# 239382
Sunagawa, Hokkaido, 073-0164
Tokyo Metropolitan Geriatric /ID# 249448
tabashi City, Tokyo, 173-0015
Duplicate_Teikyo University Hospital /ID# 247896
tabashi City, Tokyo, 173-8606
Tachikawa Hospital /ID# 245878
Tachikawa
Eiju General Hospital /ID# 243763
Taitō City, Tokyo, 110-0015
Takatsuki Red Cross Hospital /ID# 266756
Takatsuki, 569-1045
Osaka Medical and Pharmaceutical University Hospital /ID# 249440
Takatsuki-shi, Osaka, 569-8686
Japanese Red Cross Takayama Hospital /ID# 240568
Takayama, Gifu, 506-0025
Kumamoto Kenhoku Hospital /ID# 258240
Tamana-shi, Kumamoto, 865-0005
Hyogo Prefectural Tamba Medical Center /ID# 240884
Tamba-shi, Hyōgo, 669-3464
Social Insurance Kinan Hosp /ID# 251684
Tanabe-shi, Wakayama, 646-0011
Hyogo College of Medicine Sasayama Medical Center /ID# 240888
Tanbasasayama-shi, Hyōgo, 669-2321
Tatebayashi Kosei General Hospital /ID# 252188
Tatebayashi-shi, Gunma, 374-0055
Tenri Hospital /ID# 250855
Tenri-shi, Nara, 632-8552
Tokushima University Hospital /ID# 252572
Tokushima, Tokushima, 770-8503
Toshiba General Hospital /ID# 250294
Tokyo, 140-8522
Ehime University Hospital /ID# 244207
Toon-shi, Ehime, 791-0295
JA Toride Medical Center /ID# 240573
Toride-shi, Ibaraki, 302-0022
Tottori Prefectural Central Ho /ID# 245877
Tottori-shi, Tottori, 680-0901
Toyama Hospital /ID# 243779
Toyama, 939-8511
Toyohashi Municipal Hospital /ID# 243784
Toyohashi, Aichi-ken, 441-8570
Toyokawa City Hospital /ID# 242707
Toyokawa-shi, Aichi-ken, 442-8561
Toyota Memorial Hospital /ID# 242175
Toyota-shi, Aichi-ken, 471-8513
Takeuchi Hospital /ID# 238750
Tsu, Mie-ken, 514-0031
University of Tsukuba Hospital /ID# 242023
Tsukuba, Ibaraki, 305-8576
Yamaguchi University Hospital /ID# 245060
Ube-shi, Yamaguchi, 755-8505
Uji Tokushukai Medical Center /ID# 241876
Uji-shi, Kyoto, 611-0042
Kumamoto Minami National Hospital /ID# 242169
Uki, Kumamoto, 869-0524
Tochigi Cancer Center /ID# 249445
Utsunomiya, Tochigi, 320-0834
Wakayama Rosai Hospital /ID# 250293
Wakayama, Wakayama, 640-8505
Wakkanai City Hospital /ID# 243782
Wakkanai, Hokkaido, 097-0022
NHO Saitama National Hospital /ID# 245061
Wako-shi, Saitama, 351-0102
Yamagata University Hospital /ID# 246763
Yamagata, Yamagata, 990-9585
Shonai Hospital /ID# 254514
Yamagata, 9978515
Ogori Daiichi General Hospital /ID# 246761
Yamaguchi, Yamaguchi, 754-0002
Nagata Hospital /ID# 256180
Yanagawa-shi, Fukuoka, 832-0059
Yao Tokushukai General Hospital /ID# 247884
Yao, Osaka, 581-0011
JCHO Kumamoto General Hospital /ID# 248779
Yatsushiro, Kumamoto, 866-0856
Yokohama City University Medical Center /ID# 248777
Yokohama, Kanagawa, 232-0024
Saiseikai Yokohamashi Nanbu Hospital /ID# 247955
Yokohama, Kanagawa, 234-8503
St. Marianna University School of Medicine Yokohama City Seibu Hospital /ID# 266803
Yokohama, Kanagawa, 241-0811
Kanagawa Cancer Center /ID# 246822
Yokohama, Kanagawa, 241-8515
Yonago Medical Center /ID# 240572
Yonago-shi, Tottori, 683-0006
Tottori University Hospital /ID# 244215
Yonago-shi, Tottori, 683-8504
Oita University Hospital /ID# 261976
Yufu, Oita Prefecture, 879-5503
Toshima Hospital /ID# 240878
板橋区, Tokyo, 173-0015
Hara Hospital /ID# 244846
泉大津市, Osaka, 595-0006
Hyogo Prefectural Awaji Medical Center /ID# 240823
洲本市, Hyōgo, 656-0021
About this study
Official title: A Post-marketing Observational Study for Venetoclax in Patients Diagnosed With Acute Myeloid Leukemia in Japan
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults. This study will assess how safe and effective oral venetoclax is in participants with AML. Adverse events and change in disease activity will be monitored under routine clinical practice.
Venetoclax is an approved drug to treat Acute Myeloid Leukemia (AML). Around 400 participants of any age who are treated with oral venetoclax tablets for AML in accordance with the approved label will be enrolled in the study across Japan.
Read more
Participants will be followed up to 52 weeks following the first dose of oral venetoclax tablets.
There is expected to be no additional burden for participants in this study. Data will be collected by information provided by participating physicians based on routine medical records.
- Conditions
- Acute Myeloid Leukemia (AML)
- Keywords
- Acute Myeloid Leukemia (AML), Cancer, Venetoclax, Venclexta, Venclyxto
- Medical subject headings
- Leukemia, Myeloid, Acute, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants Treated With Venetoclax | Participants who are administrated venetoclax for treatment of AML under routine clinical practice. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With ≥ Grade 3 Neutropenia of Venetoclax Regimens With Unfit Acute Myeloid Leukemia (AML)
Percentage of participants with a high grade (≥ Grade 3) protocol specified neutropenia during and after treatment with venetoclax.
Measured: Up to 52 weeks.
Secondary outcomes (10)
Percentage of Participants With Febrile Neutropenia and Thrombocytopenia
Percentage of participants with protocol specified febrile neutropenia and thrombocytopenia during and after treatment with venetoclax.
Measured: Up to 52 weeks
Percentage of Participants With Tumor Lysis Syndrome (TLS)
Percentage of participants with protocol specified TLS during and after treatment with venetoclax.
Measured: Up to 52 weeks
Percentage of Participants Reported >= Grade 3 Adverse Events (AE)/Adverse Drug Reactions (ADR)
Grade 3 and above AE/ADR are serious adverse event (SAE) that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
Measured: Up to 52 weeks
Percentage of Participants Reported Adverse Events (AE)/Adverse Drug Reaction (ADR)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either definitely related, probably related, possibly related or unrelated.
Measured: Up to 52 weeks
Percentage of Participants With AE/ADR When Used Concomitantly With CYP3A Inhibitors or Growth Colony Stimulating Factor (G-CSF)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either definitely related, probably related, possibly related or unrelated.
Measured: Up to 52 weeks
Percentage of Participants With Composite Complete Remission Rate (CR + CRi)
Composite Complete remission (CRc) is defined as Complete Remission (CR) + CRi (CR with incomplete blood count recovery) based on protocol criteria.
Measured: Up to 52 weeks
Median Time to Best Response
Time to Best Response is measured as the time in months from the first dose of study treatment to the date of first documented documentation of a confirmed response of partial response (PR) or better.
Measured: Up to 52 weeks.
Median Treatment Duration
Median time for duration of oral venetoclax treatment in participants with Acute Myeloid Leukemia.
Measured: Up to 52 weeks
Median Overall Survival
Time from the date of first oral Venetoclax intake to the date of death from any cause.
Measured: Up to 52 weeks
Median Duration of Composite Complete Remission
Time from the date of first oral Venetoclax intake and the date of the assessment having documented Complete Remission with incomplete Hematologic recovery (CRi).
Measured: Up to 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2021
- Study start28 May 2021
- Primary completion30 Apr 2024
- Study completion30 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myeloid Leukemia (AML)Studies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 424 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04813263
- Sponsor's protocol ID
- P20-408
- Status last verified
- Apr 2025
- First submitted
- 22 Mar 2021
- Last updated
- 27 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Post-marketing Observational Study for Venetoclax in Patients Diagnosed With Acute Myeloid Leukemia in Japan
- ClinicalTrials.gov ID
- NCT04813263
- Acronym / sponsor ID
- P20-408
- Conditions
- Acute Myeloid Leukemia (AML)
- Keywords
- Acute Myeloid Leukemia (AML), Cancer, Venetoclax, Venclexta, Venclyxto
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 424 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 28 May 2021 (actual)
- Primary completion
- 30 Apr 2024 (actual)
- Study completion
- 30 Apr 2024 (actual)
- First posted
- 24 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults. This study will assess how safe and effective oral venetoclax is in participants with AML. Adverse events and change in disease activity will be monitored under routine clinical practice.
Venetoclax is an approved drug to treat Acute Myeloid Leukemia (AML). Around 400 participants of any age who are treated with oral venetoclax tablets for AML in accordance with the approved label will be enrolled in the study across Japan.
Participants will be followed up to 52 weeks following the first dose of oral venetoclax tablets.
There is expected to be no additional burden for participants in this study. Data will be collected by information provided by participating physicians based on routine medical records.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants Treated With Venetoclax | – | –Participants who are administrated venetoclax for treatment of AML under routine clinical practice. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Participants who are prescribed venetoclax for the treatment of Acute Myeloid Leukemia (AML) in routine clinical practice across Japan.
Key inclusion criteria (1 listed)
- All participants who are administered venetoclax for treatment of AML.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of Participants With ≥ Grade 3 Neutropenia of Venetoclax Regimens With Unfit Acute Myeloid Leukemia (AML)
Time frame: Up to 52 weeks.
Percentage of participants with a high grade (≥ Grade 3) protocol specified neutropenia during and after treatment with venetoclax.
10 secondary outcomes
Percentage of Participants With Febrile Neutropenia and Thrombocytopenia
Time frame: Up to 52 weeks
Percentage of Participants With Tumor Lysis Syndrome (TLS)
Time frame: Up to 52 weeks
Percentage of Participants Reported >= Grade 3 Adverse Events (AE)/Adverse Drug Reactions (ADR)
Time frame: Up to 52 weeks
Percentage of Participants Reported Adverse Events (AE)/Adverse Drug Reaction (ADR)
Time frame: Up to 52 weeks
Percentage of Participants With AE/ADR When Used Concomitantly With CYP3A Inhibitors or Growth Colony Stimulating Factor (G-CSF)
Time frame: Up to 52 weeks
Percentage of Participants With Composite Complete Remission Rate (CR + CRi)
Time frame: Up to 52 weeks
Median Time to Best Response
Time frame: Up to 52 weeks.
Median Treatment Duration
Time frame: Up to 52 weeks
Median Overall Survival
Time frame: Up to 52 weeks
Median Duration of Composite Complete Remission
Time frame: Up to 52 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Myeloid Leukemia (AML)
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 1/2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
281 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myeloid Leukemia (AML), run by AbbVie at 281 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 281 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With ≥ Grade 3 Neutropenia of Venetoclax Regimens With Unfit Acute Myeloid Leukemia (AML) (time frame: Up to 52 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2025.